Vivos Therapeutics Stock Buy Hold or Sell Recommendation
| VVOS Stock | USD 3.38 0.18 5.62% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Vivos Therapeutics is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Vivos Therapeutics given historical horizon and risk tolerance towards Vivos Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Vivos Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Vivos Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Vivos Stock please use our How to Invest in Vivos Therapeutics guide. Note, we conduct extensive research on individual companies such as Vivos and provide practical buy, sell, or hold advice based on investors' constraints. Vivos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
Vivos |
Execute Vivos Therapeutics Buy or Sell Advice
The Vivos recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Vivos Therapeutics. Macroaxis does not own or have any residual interests in Vivos Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Vivos Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Vivos Therapeutics Trading Alerts and Improvement Suggestions
| Vivos Therapeutics is way too risky over 90 days horizon | |
| Vivos Therapeutics appears to be risky and price may revert if volatility continues | |
| Vivos Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 13.8 M. Net Loss for the year was (13.58 M) with profit before overhead, payroll, taxes, and interest of 12.6 M. | |
| Vivos Therapeutics currently holds about 17.83 M in cash with (11.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.77. | |
| Vivos Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Vivos Therapeutics price target lowered to 6 from 8.25 at Alliance Global Partners - TipRanks |
Vivos Therapeutics Returns Distribution Density
The distribution of Vivos Therapeutics' historical returns is an attempt to chart the uncertainty of Vivos Therapeutics' future price movements. The chart of the probability distribution of Vivos Therapeutics daily returns describes the distribution of returns around its average expected value. We use Vivos Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Vivos Therapeutics returns is essential to provide solid investment advice for Vivos Therapeutics.
| Mean Return | 0.56 | Value At Risk | -7.14 | Potential Upside | 9.52 | Standard Deviation | 8.22 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Vivos Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Vivos Stock Institutional Investors
The Vivos Therapeutics' institutional investors refer to entities that pool money to purchase Vivos Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Group One Trading, Lp | 2024-06-30 | 228 | Ronald Blue Trust, Inc. | 2024-09-30 | 160 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 136 | Bank Of America Corp | 2024-06-30 | 103 | Kozak & Associates, Inc. | 2024-09-30 | 49.0 | Global Retirement Partners, Llc. | 2024-09-30 | 23.0 | Td Waterhouse Canada Inc | 2024-06-30 | 12.0 | Steward Partners Investment Advisory, Llc | 2024-06-30 | 8.0 | Royal Bank Of Canada | 2024-06-30 | 7.0 | Strategic Wealth Designers | 2024-09-30 | 100 K | Geode Capital Management, Llc | 2024-09-30 | 28.8 K |
Vivos Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | 86.2K | (120.3K) | (2.6M) | (924K) | (888K) | (932.4K) | |
| Change In Cash | (785.4K) | 17.7M | 5.8M | (20.5M) | (1.9M) | (1.8M) | |
| Free Cash Flow | (5.5M) | (5.8M) | (18.1M) | (20.5M) | (12.8M) | (13.4M) | |
| Depreciation | 751.2K | 717.9K | 733K | 669K | 621K | 547.0K | |
| Other Non Cash Items | 83.1K | 3.9M | (9K) | (518K) | (1.6M) | (1.5M) | |
| Capital Expenditures | 175.6K | 120.3K | 2.4M | 924K | 853K | 1.0M | |
| Net Income | (10.8M) | (12.1M) | (20.3M) | (23.8M) | (13.6M) | (14.3M) | |
| End Period Cash Flow | 469.4K | 18.2M | 24.0M | 3.5M | 1.6M | 1.6M |
Vivos Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Vivos Therapeutics or Health Care Equipment & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Vivos Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Vivos stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.47 | |
β | Beta against Dow Jones | 0.65 | |
σ | Overall volatility | 8.31 | |
Ir | Information ratio | 0.05 |
Vivos Therapeutics Volatility Alert
Vivos Therapeutics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Vivos Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Vivos Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Vivos Therapeutics Fundamentals Vs Peers
Comparing Vivos Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Vivos Therapeutics' direct or indirect competition across all of the common fundamentals between Vivos Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Vivos Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Vivos Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Vivos Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Vivos Therapeutics to competition |
| Fundamentals | Vivos Therapeutics | Peer Average |
| Return On Equity | -2.85 | -0.31 |
| Return On Asset | -0.57 | -0.14 |
| Profit Margin | (0.86) % | (1.27) % |
| Operating Margin | (0.48) % | (5.51) % |
| Current Valuation | 10.8 M | 16.62 B |
| Shares Outstanding | 4.84 M | 571.82 M |
| Shares Owned By Insiders | 1.51 % | 10.09 % |
| Shares Owned By Institutions | 13.72 % | 39.21 % |
| Number Of Shares Shorted | 95.09 K | 4.71 M |
| Price To Book | 2.02 X | 9.51 X |
| Price To Sales | 1.10 X | 11.42 X |
| Revenue | 13.8 M | 9.43 B |
| Gross Profit | 12.6 M | 27.38 B |
| EBITDA | (16.68 M) | 3.9 B |
| Net Income | (13.58 M) | 570.98 M |
| Cash And Equivalents | 17.83 M | 2.7 B |
| Cash Per Share | 0.77 X | 5.01 X |
| Total Debt | 2 M | 5.32 B |
| Debt To Equity | 0.10 % | 48.70 % |
| Current Ratio | 3.15 X | 2.16 X |
| Book Value Per Share | 0.22 X | 1.93 K |
| Cash Flow From Operations | (11.95 M) | 971.22 M |
| Short Ratio | 0.66 X | 4.00 X |
| Earnings Per Share | (4.99) X | 3.12 X |
| Target Price | 6.3 | |
| Number Of Employees | 114 | 18.84 K |
| Beta | 7.68 | -0.15 |
| Market Capitalization | 15.47 M | 19.03 B |
| Total Asset | 10.73 M | 29.47 B |
| Retained Earnings | (93.05 M) | 9.33 B |
| Working Capital | (4.83 M) | 1.48 B |
| Net Asset | 10.73 M |
Note: Acquisition by Huntsman Ronald Kirk of 5000 shares of Vivos Therapeutics at 4.31 subject to Rule 16b-3 [view details]
Vivos Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Vivos . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Vivos Therapeutics Buy or Sell Advice
When is the right time to buy or sell Vivos Therapeutics? Buying financial instruments such as Vivos Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Vivos Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Funds Thematic Idea Now
Aggressive Funds
Funds or Etfs that attempt to achieve high capital gains by investing in companies with high growth potential and above average risk. The Aggressive Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Vivos Stock Analysis
When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.